US privately-held biotech start-up Sigilon Therapeutics has signed its first major deal for the use of its encapsulated cell therapy Afibromer.
The agreement is with US pharma major Eli Lilly (NYSE: LLY) for a global collaboration to develop encapsulated cell therapies for the potential treatment of type 1 diabetes.
Interestingly, in January this year, Lilly’s former vice president of business development for emerging technology and innovation, David Moller, joined Sigilon as chief scientific officer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze